Not All Tariffs Hurt the Same - A Smarter Look at the U.S.-India Risk

A 25% U.S. tariff on Indian exports sounds serious but how serious is it for investors? Let's break this down rationally: Macro Impact is Limited: U.S. exports form only around 2% of India's GDP, so from a macro standpoint, this isn't a major shock to the system. But Sector Impact Is Uneven: Industries like IT and Pharma derive 30-70% of their revenues from the U.S. So yes some businesses are deeply exposed. But the question isn't just about exposure... It's about alternatives. Here's how to think about it: If U.S. buyers have no real substitutes (e.g., if China has higher tariffs and India is the next best option), then even at 25%, demand may only drop modestly especially for critical services like software or generics. If cheaper or untariffed substitutes exist (say, Vietnam or Mexico), the demand shift could be sharper -especially for low-complexity, price-sensitive exports. So the risk isn't flat - it varies by product, margin, and market dynamics. This is more of a framework to assess exposure, not an immediate trigger to act. Investor Takeaway Don't overhaul your portfolio. But if this situation worries you: Consider trimming exposure to heavily U.S.-dependent firms, especially in low-margin categories. Rebalance into companies with India-centric demand or diversified geographies. No need to overreact - but definitely a time to rethink concentration risk.